Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility by Pollanen, Petra M. et al.
ARTICLE
Characterisation of rapid progressors to type 1 diabetes
among children with HLA-conferred disease susceptibility
Petra M. Pöllänen1,2 & Johanna Lempainen3 & Antti-Pekka Laine3 & Jorma Toppari4 &
Riitta Veijola5 & Paula Vähäsalo5 & Jorma Ilonen3 & Heli Siljander1,2 & Mikael Knip1,2,6,7
Received: 30 May 2016 /Accepted: 17 February 2017 /Published online: 31 March 2017
# Springer-Verlag Berlin Heidelberg 2017
Abstract
Aims/hypothesis In this study, we aimed to characterise rapid
progressors to type 1 diabetes among children recruited from
the general population, on the basis of HLA-conferred disease
susceptibility.
Methods We monitored 7410 HLA-predisposed children par-
ticipating in the Finnish Type 1 Diabetes Prediction and
Prevention (DIPP) study for the development of beta cell au-
toimmunity and type 1 diabetes from birth over a median
follow-up time of 16.2 years (range 0.9–21.1 years). Islet cell
antibodies (ICA) and autoantibodies to insulin (IAA), GAD
(GADA) and islet antigen 2 (IA-2A) were assessed as markers
of beta cell autoimmunity. Rapid progression was defined as
progression to clinical type 1 diabetes within 1.5 years of
autoantibody seroconversion. We analysed the association be-
tween rapid progression and demographic and autoantibody
characteristics as well as genetic markers, including 25 non-
HLA SNPs predisposing to type 1 diabetes.
Results Altogether, 1550 children (21%) tested positive for at
least one diabetes-associated autoantibody in at least two sam-
ples, and 248 (16%) of seroconverters progressed to type 1
diabetes by the end of 2015. The median time from serocon-
version to diagnosis was 0.51 years in rapid progressors
(n = 42, 17%) and 5.4 years in slower progressors. Rapid
progression was observed both among young (<5 years) and
early pubertal children (>7 years), resulting in a double-peak
distribution of seroconversion age. Compared with slower
progressors, rapid progressors had a higher frequency of pos-
itivity for multiple (≥2) autoantibodies and had higher titres of
ICA, IAA and IA-2A at seroconversion, and there was a
higher prevalence of the secretor genotype in the FUT2 gene
among those carrying the high-risk HLA genotype. Compared
with autoantibody-positive non-progressors, rapid progressors
were younger, were more likely to carry the high-risk HLA
genotype and a predisposing SNP in the PTPN22 gene, had
higher frequency of ICA, IAA, GADA and IA-2A positivity
and multipositivity, and had higher titres of all four autoanti-
bodies at seroconversion.
Conclusions/interpretation At seroconversion, individuals
with rapid progression to type 1 diabetes were characterised
by a younger age, higher autoantibody titres, positivity for mul-
tiple autoantibodies and higher prevalence of a FUT2 SNP. The
double-peak profile for seroconversion age among the rapid
progressors demonstrates for the first time that rapid progres-
sion may take place not only in young children but also in
children in early puberty. Rapid progressors might benefit from
careful clinical follow-up and early preventive measures.
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Type 1 diabetes is one of the most common chronic autoim-
mune diseases in children and adolescents. It is characterised
by immune-mediated destruction of pancreatic insulin-
producing beta cells, eventually leading to total insulin defi-
ciency. Type 1 diabetes is preceded by an asymptomatic predi-
abetic period, during which autoantibodies against beta cell
structures can be detected in the peripheral circulation [1].
Prediabetic autoantibodies are considered to reflect ongoing
islet-specific immune activity and are thus suitable for disease
prediction. Previous observations in prediabetic individuals
have shown that the duration of the preclinical period is highly
variable, ranging from only a few months to more than two
decades [2]. The variable duration of the preclinical phase sug-
gests that genetic and immunological characteristics and envi-
ronmental factors might differ between individuals with rapidly
and slowly progressing forms of beta cell autoimmunity.
Earlier studies of prediabetic beta cell autoimmunity and
progression to clinical diabetes found that individuals at an in-
creased disease risk can be identified based on risk-associated
HLA genotypes together with islet-specific autoantibodies in
their peripheral circulation [3, 4]. However, the timescale for
progression to clinical type 1 diabetes and the factors influenc-
ing the progression rate remain relatively poorly characterised.
In the German BABYDIAB study characterising rapid vs slow
progression to type 1 diabetes in multiple autoantibody-positive
children, no significant differences were detected in prediabetic
autoantibody profiles or HLA predisposition between rapid and
slow progressors, except for delayed development of IA-2A in
slow progressors. In addition, some differences in the distribu-
tion of non-HLA alleles were reported [5].
This prospective study describes the demographic, genetic
and immunological characteristics of prediabetic beta cell au-
toimmunity associated with rapid progression to type 1
diabetes in children with HLA-conferred disease susceptibili-
ty who were recruited from the general population.
Methods
Study participants and their samples The Finnish Type 1
Diabetes Prediction and Prevention (DIPP) study is an ongo-
ing longitudinal observational birth cohort study involving
three Finnish university hospitals. The objective of the DIPP
study is to monitor the appearance of prediabetic islet autoim-
munity in children with HLA-defined disease predisposition
and identify interventions for delaying or preventing clinical
type 1 diabetes in at-risk individuals. Recruitment began in
Turku University Hospital in 1994, in Oulu University
Hospital in 1995 and in Tampere University Hospital in
1997. The three hospitals cover a population of approximately
1.4 million (26% of the total population in Finland), and the
number of annual births in all three hospitals is around 14,000
(24% of the total number of annual births in Finland).
The local ethical committees of participating hospitals ap-
proved the DIPP study protocol. The study has been carried
out in accordance with the principles of the Declaration of
Helsinki. The legal representatives of all newborn infants gave
written informed consent for cord blood samples to be taken
for HLA genotyping. Infants with severe congenital abnor-
malities or disease were excluded from the study, as were
families sharing no common language with the study person-
nel (i.e. Finnish, Swedish or English). Infants with eligible
HLA-DR/DQ risk genotypes were invited to participate in im-
munological surveillance and clinical follow-up, which started
at the age of 3 months [6].
Immunological follow-up was performed using venous
blood samples obtained at regular clinical visits. In Oulu and
Tampere hospitals, samples were taken at 3, 6, 12, 18 and
24 months of age and annually thereafter. In Turku hospital,
samples were obtained every 3 months from birth until 2 years
of age and then once every 6months. Children presentingwith
autoantibodies were invited to follow-up visits every 3months
at all three study centres. All serum samples collected from
study participants were stored at −70°C until analysis.
We followed 7410 children (52.6% boys) with HLA pre-
disposition to type 1 diabetes from birth (Table 1). These chil-
dren had participated in the DIPP follow-up for at least 1 year
before 2003 or had developed clinical type 1 diabetes before
the age of 1 year by the end of 2003 (Fig. 1). Thirteen children
(0.2%) progressed to clinical type 1 diabetes without develop-
ing diabetes-associated autoantibodies and were thus exclud-
ed from the autoantibody analyses. Twelve of these children
had a delay of 3–12 years from the last autoantibody sampling
to diagnosis, which probably contributed to the absence of
detectable autoantibodies. Autoantibody data for these chil-
dren were not available at the time of diagnosis, except for
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one child who was autoantibody positive at diagnosis accord-
ing to the Finnish Paediatric Diabetes Register.
Genetic screening PCR amplification followed by
hybridisation with lanthanide-labelled sequence-specific oligo-
nucleotide probes using time-resolved fluorometry was used to
genotype cord blood samples for the major type 1 diabetes risk-
associated HLA DR-DQ haplotypes [6, 7]. Eligible children
carried either the high-risk HLA-DQB1*02/*03:02 genotype
or themoderate risk-associatedHLA-DQB1*03:02/x genotypes
(x ≠ DQB1*02, 03:01 or 06:02) [8, 9]. SNPs of 25 non-HLA
genes predisposing to type 1 diabetes were analysed to assess
associations with rapid disease progression (electronic supple-
mentary material [ESM] Table 1) [10–14]. SNP genotyping
was performed using the Sequenom (San Diego, California,
USA) platform at the Genome Center of Eastern Finland,
University of Eastern Finland, Kuopio, Finland, and was con-
sidered successful when the failure rate for the SNP marker
analysis was <10% [15].
Analysis of diabetes-associated autoantibodiesDiabetes-as-
sociated autoantibodies were analysed in the Research
Laboratory, Department of Pediatrics, University of Oulu,
Oulu, Finland. Islet cell antibodies (ICA) were used as the
primary screening tool for beta cell autoimmunity until the
end of 2002. If a child was ICA positive or progressed to
clinical type 1 diabetes during the follow-up, all of his/her
prior and subsequent samples were also analysed for insulin
Table 1 Clinical characteristics: study population
Characteristic Median (range)
Follow-up time, years 16.2 (0.9–21.1)
Time from seroconversion to diagnosis, years 4.0 (0.0–17.0)
Age at seroconversion, yearsa 5.0 (0.2–15.1)
Age at diagnosis, years 7.6 (0.9–18.0)
Autoantibody titre at seroconversiona
ICA, JDFU 5 (3–668)
IAA, RU 7.9 (3.5–148.7)
GADA, RU 19.0 (5.4–342.1)
IA-2A, RU 12.6 (0.4–121.0)
n = 7410
aVariables used in Cox regression analyses
HLA screening 















excluded from the analysis
n=892 (10.7%)






Developed clinical type 1 diabetes
without known autoantibody positivity 
n=13 (0.2%)
Tested positive for ≥1 autoantibody in at least 
one sample during the follow-up
n=1659 (22.4%) 
First autoantibody-positive sample
at the diagnosis of T1D
n=14 (0.2%)
Autoantibody positivity
before the diagnosis of T1D
n=1645 (22.2%)
Tested positive for ≥1 autoantibody in at least
two samples during the follow-up
n=1550 (20.9%)
Unaffected by T1D 
by 31 December 2015
n=1302 (84.0%)
Progressed to T1D
by 31 December 2015
n=248 (16.0%)
Rapid progressors
Time from seroconversion to diagnosis ≤1.5 years 
n=42 (16.9%)
Slower progressors 
Time from seroconversion to diagnosis >1.5 years
n=206 (83.1%)
Fig. 1 The DIPP study cohort. T1D, type 1 diabetes
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autoantibodies (IAA), GAD autoantibodies (GADA) and islet
antigen 2 autoantibodies (IA-2A). Since 2003, all samples
were analysed for ICA, IAA, GADA and IA-2A for study
participants born in 2003 and later.
ICAwere measured using a standardised indirect immuno-
fluorescence staining method on frozen human pancreas sec-
tions from a blood group O donor, as described previously
[16]. The cut-off limit for ICA positivity was 2.5 Juvenile
Diabetes Foundation units (JDFU). The biochemical autoan-
tibodies IAA, GADA and IA-2Awere analysed with specific
radiobinding assays, as previously described [17–19]. Titres
of the biochemical autoantibodies were expressed in relative
units (RU), representing specific binding of autoantibodies to
their cognate antigens. RU were based on a standard curve
prepared for each assay plate using MultiCalc software
(PerkinElmer Life Sciences–Wallac, Turku, Finland). Cut-off
values for positivity were defined as the 99th percentile levels
in 370–374 healthy Finnish children: IAA, 3.48 RU; GADA,
5.36 RU; IA-2A, 0.43 RU. All study samples with titres be-
tween the 97th and 99.5th percentiles of the reference popu-
lation values were reanalysed to confirm the result.
According to the Diabetes Autoantibody Standardization
Program and Islet Autoantibody Standardization Program
workshop results in 2010–2015, disease sensitivities for the
IAA, GADA and IA-2A radiobinding assays were 36–62%,
64–88% and 62–72%, respectively. The corresponding dis-
ease specificities were 94–98%, 94–99% and 93–100%,
respectively.
Definitions The time point for seroconversion was defined as
the date of the first autoantibody-positive sample. Confirmed
autoantibody positivity was defined as positivity for at least
one autoantibody in at least two samples. Five progressors
diagnosed with classical type 1 diabetes but only one
autoantibody-positive sample before diagnosis were consid-
ered autoantibody-positive progressors. Multipositivity was
defined as positivity for two or more autoantibodies in the
same sample. The diagnosis of diabetes was based on WHO
criteria [20]. Prediabetes was defined as the detection of
diabetes-associated autoantibodies in the peripheral circula-
tion before the diagnosis of clinical type 1 diabetes.
Disease progression was considered to be rapid when type
1 diabetes was diagnosed within 1.5 years of seroconversion
to autoantibody positivity. This cut-off limit was partly data
driven and partly based on practical considerations: (1) these
rapid progressors (17% of all progressors) represent one of the
main targets for future preventive interventions; (2) if the pre-
ventive treatment is a success, results become obvious within
a short period; and (3) it takes a couple of months to confirm
the autoantibody results, exclude overt disease and start pre-
ventive treatment. The term ‘data driven’ indicates that we set
out to identify about one-fifth of the study population with the
most rapid disease progression.
Data management and statistical analyses Multiple para-
metric and non-parametric statistical analyses were performed
using IBM SPSS Statistics for Macintosh predictive analytics
software (version 22.0, Armonk, NY, USA). The CI was set at
95% and statistical significance was set at p < 0.05 (two-
tailed). Cross-tabulation with Pearson’s χ2 test and Fisher’s
exact test, as well as the Mann–Whitney U test or Kruskal–
Wallis test, were used to test for significant differences be-
tween the groups. Survival distributions according to SNP
genotype were tested using the logrank test (Kaplan–Meier
analysis). In SNP analyses, Bonferroni correction was used
to control for multiple comparisons. Independent variables
predicting clinical type 1 diabetes within 1.5 years of serocon-
version were tested using the Cox proportional hazards sur-
vival model. Group-specific differences in autoantibody levels
were analysed only among autoantibody-positive participants
(except in Table 2).
Results
Prevalence of HLA risk genotypes and development of
diabetes-associated autoantibodies We followed 7410
HLA-predisposed children from birth for amedian of 16.2 years
(range 0.9–21.1 years). Altogether, 1550 children (20.9%) test-
ed positive for at least one autoantibody in at least two samples
by the end of 2015; 248 (16.0%) of autoantibody-positive chil-
dren progressed to clinical type 1 diabetes. The median age at
seroconversion was 5.0 years (Table 1, ESM Fig. 1a). The me-
dian time from seroconversion to diagnosis was 0.51 years in
rapid progressors (n = 42, 16.9% of progressors) and 5.37 years
in slower progressors (n = 206; Table 3, ESM Fig. 1b).
Table 2 Clinical characteristics: young vs older rapid progressors
Characteristic Rapid progressors p value
Younga (n = 36) Olderb (n = 6)
Autoantibody titre at seroconversion
ICA, JDFU 5 (0–320) 49 (0–85) 0.15
IAA, RU 9.5 (4.3–66.2) 1.4 (0.1–13.0) 0.001
GADA, RU 5.1 (0.1–310.4) 97.7 (5.6–158.5) 0.004
IA-2A, RU 0.11 (0.05–108.6) 0.12 (0.05–52.51) 0.77
Age at seroconversion,
years
1.4 (0.3–4.1) 9.0 (7.0–13.1)




0.41 (0.02–1.45) 0.73 (0.59–1.19)
Data are medians (range)
a Early childhood (<5 years old)
b Early puberty (>7 years old)
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In all, the prevalence at seroconversion was 16.5%
(n = 1224) for ICA, 4.1% for IAA (n = 304), 3.6% for
GADA (n = 264), 1.1% for IA-2A (n = 84), and 2.9% for
multipositivity (n = 213; Table 4). At seroconversion, 117 chil-
dren (1.6%) were positive for at least two biochemical autoan-
tibodies (IAA, GADA and/or IA-2A). Of the 1224 initially
ICA-positive children, 26 (2.1%) were rapid progressors and
116 (9.5%) were slower progressors, while 60 (4.9%) of those
who were initially multipositive and 1022 (83.5%) who were
initially single autoantibody positive have not yet progressed to
diabetes (non-progressors). Among the 304 initially IAA-
positive children, 34 (11.2%) were rapid progressors, 136
(44.7%) were slower progressors, 37 (12.2%) are multipositive
non-progressors and 97 (31.9%) are single autoantibody-
positive non-progressors. Correspondingly, of the 264 initially
GADA positive and 84 initially IA-2A positive children,
24 (9.1%) and 11 (13.1%) were classified as rapid progressors,
93 (35.2%) and 43 (51.2%) as slower progressors, 48 (18.2%)
and 16 (19.0%) as multipositive non-progressors, and 99
(37.5%) and 14 (16.7%) as single autoantibody-positive non-
progressors, respectively.
Rapid vs slower disease development In comparison with
slower progressors, rapid progressors had higher titres of ICA,
IAA and IA-2A, and a higher frequency of multipositivity at
seroconversion (Table 5, ESM Fig. 2). There were no significant
differences between groups regarding sex, HLA genotypes, age
at seroconversion or positivity for any of the four diabetes-
associated autoantibodies (Table 5). Of the diabetes-associated
autoantibodies, IA-2A had the highest specificity (95%, n = 11)
and ICA and IAA the highest sensitivities (62% [n = 26] and
81% [n = 34], respectively) for rapid disease progression.
Rapid progressors vs autoantibody-positive non-progressors
Compared with autoantibody-positive non-progressors, rapid
progressors were younger, were more likely to carry the high-
riskHLA-DQB1*02/*03:02 genotype, had higher frequencies of
Table 3 Clinical characteristics: rapid progressors vs slower progressors and AAB-positive non-progressors
Characteristic Progressors Non-progressors




p valueb p valuec
AAB titre at seroconversion
ICA, JDFU 34.5 (4–320) 10 (3–668) 0.001 4 (3–512) <0.001 <0.001
IAA, RU 10.5 (4.3–66.2) 8.8 (3.5–81.0) 0.050 6.9 (3.5–148.7) <0.001 0.002
GADA, RU 32.1 (5.6–310.4) 28.0 (5.8–189.5) 0.51 13.5 (5.4–342.1) 0.01 <0.001
IA-2A, RU 52.5 (2.6–108.6) 16.4 (0.4–121.0) 0.04 2.3 (0.5–88.9) <0.001 0.005
Age at seroconversion, years 1.5 (0.3–13.8) 1.9 (0.3–12.0) 0.24 6.0 (0.2–15.1) <0.001 <0.001
Age at diagnosis, years 2.4 (0.9–14.6) 8.4 (2.1–18.0)
Time from seroconversion to diagnosis, years 0.51 (0.02–1.45) 5.37 (1.53–17.0)
Follow-up time, years 2.4 (0.9–14.6) 8.4 (2.1–18.0) 16.5 (12.4–21.1)
Data are medians (range)
a Rapid progressors vs slower progressors
b Rapid progressors vs autoantibody-positive non-progressors
c Slower progressors vs autoantibody-positive non-progressors
AAB, autoantibody
Table 4 HLA genotype, AAB positivity and disease progression: study
population
Characteristic n (%)
Sex (male)a 3895 (52.6)
HLA genotypea
High-risk, DQB1*02/*0302 1575 (21.3)
Moderate risk, DQB1*0302/xb 5835 (78.7)
AAB positivity at seroconversiona






Progression to clinical type 1 diabetes
During follow-up 248 (16.0)
Within 1.5 years of seroconversion 42 (16.9)c
n = 7410
aVariables in the Cox regression analyses
bWhere x ≠ DQB1*02, *03:01 or *06:02
c Percentage of progressors
AAB, autoantibody
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ICA, IAA, GADA and IA-2A positivity and multipositivity,
higher titres of ICA, IAA, GADA, and IA-2A, and more fre-
quently tested positive for at least two biochemical autoanti-
bodies (IAA, GADA, IA-2A; 48% vs 2%; p < 0.001). There
was no significant difference in sex distribution between groups
(Table 5). Compared with slower progressors, a smaller propor-
tion of autoantibody-positive non-progressors carried the high-
risk HLA genotype (Table 5; p < 0.001).
Double-peak profile for seroconversion age among rapid
progressors In our study population, rapid progression to type
1 diabetes occurred in two peaks: the first in early childhood
and the second in early puberty. The majority of rapid
progressors (n = 36) developed clinical diabetes before the
age of 5 years, while six children were not affected before
early puberty (at 8–14 years). No participants who underwent
seroconversion at 5–7 years of age had rapid disease progres-
sion. The distinctive distribution profile for seroconversion
age was unique to rapid progressors and was not observed in
children with slower disease progression (Fig. 2). Compared
with slower progressors, rapid progressors were more likely to
develop autoantibodies before the age of 1 year and beyond
the age of 7 years (41 vs 18%; p = 0.001).
The modest number of participants in the two age groups of
rapid progressors resulted in low power for all statistical analy-
ses. However, the frequency of IAA positivity and IAA titre at
seroconversion were higher in young vs older rapid progressors
(Tables 2 and 6). Older rapid progressors also had higher rates
of GADA positivity and higher GADA titres at seroconversion.
Older rapid progressors were predominantly boys (83%), al-
though the sex difference was non-significant, probably due to
the small numbers of individuals in these subgroups.
Association between non-HLA SNPs and disease progres-
sion rate We investigated associations between rapid disease
progression and 25 non-HLA SNPs predisposing to type 1








p valueb p valuec
High-risk HLA genotype 21 (50) 82 (40) 0.22 319 (25) <0.001 <0.001
Sex (male) 25 (60) 117 (57) 0.75 685 (53) 0.38 0.26
AAB positivity at seroconversion
ICA 26 (62) 116 (56) 0.50 1082 (83) <0.001 <0.001
IAA 34 (81) 136 (66) 0.06 134 (10) <0.001 <0.001
GADA 24 (57) 93 (45) 0.16 147 (11) <0.001 <0.001
IA-2A 11 (26) 43 (21) 0.45 30 (2) <0.001 <0.001
Multipositivity SNP 30 (71) 113 (55) 0.048 70 (5) <0.001 <0.001
FUT2 major allele G homozygositye 13 (68) 19 (28) 0.03d 23 (31) 0.06d 0.68
PTPN22 minor allele Af 19 (46) 76 (38) 0.31 167 (24) 0.03d 0.002d
Data are n (%)
a Rapid progressors vs slower progressors
b Rapid progressors vs autoantibody-positive non-progressors
c Slower progressors vs autoantibody-positive non-progressors
d Bonferroni corrected p value
e In those with the high-risk HLA genotype
f Some children were not analysed for the PTPN22 polymorphism; for rapid progressors n = 41, for slower progressors n = 200 and for AAB-positive
non-progressors n = 696
AAB, autoantibody
Fig. 2 Age at seroconversion for rapid and slower progressors. Black
bars, rapid progressors; white bars, slower progressors
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diabetes (ESM Table 1) [15]. After Bonferroni correction, the
only significant differences in disease progression were ob-
served in individuals with high-risk HLA genotype. Of these,
rapid progressors were more likely to be homozygous for the
major G allele in the FUT2 gene compared with slow
progressors (OR 5.70 [95% CI 1.89, 17.17], corrected p value
pc = 0.03; Table 5) and autoantibody-positive non-progressors
(OR 4.90 [95% CI 1.66, 14.49], p = 0.002, pc = 0.06);
Table 5). For progressors, the delay from seroconversion to
diagnosis was shorter in children with FUT2 major G allele
homozygosity than in those with the AG or AA genotype
(median 3.0 vs 4.7 years, p = 0.03). In individuals carrying
the high-risk HLA genotype and presenting with autoanti-
bodies before the age of 6 years, 34% of those with the
FUT2 GG genotype developed diabetes within 1.5 years of
seroconversion, whereas the same was true for only 8% of
those carrying the AG or AA genotype (p = 0.02; ESM
Fig. 3). Regardless of HLA genotype, a smaller proportion
of autoantibody-positive non-progressors carried the
PTPN22minor A allele compared with both rapid progressors
(OR 2.74 [95% CI 1.45, 5.19], pc = 0.03; Table 5) and slower
progressors (OR 1.93 [95% CI 1.38, 2.70], pc = 0.002).
Predictive characteristics in a multivariate model Cox re-
gression analysis identified independent variables predicting
rapid progression to type 1 diabetes within 1.5 years from se-
roconversion as the high-risk HLA genotype (HR 1.64 [95%CI
1.27, 2.12]; p < 0.001), age at seroconversion (HR 0.82 [95%
CI 0.77, 0.87]), positivity for multiple autoantibodies (HR 4.32
[95% CI 2.68, 6.99]), IAA positivity (HR 2.05 [95% CI 1.35,
3.11]) and the ICA titre at seroconversion (HR 1.003 [95% CI
1.001, 1.005]; ESM Table 2). FUT2 and PTPN22 SNPs were
not included in the model because of missing values. When
only statistically significant characteristics found in the first step
were included in a subsequent analysis, predictors of rapid pro-
gression were identified as the high-risk HLA genotype, posi-
tivity for multiple autoantibodies, an ICA titre of >10 JDFU,
IAA positivity and age at seroconversion (ESM Table 2). ICA
positivity was associated with a reduced risk of rapid progres-
sion in both analyses, most likely due to the inclusion of bio-
chemical autoantibodies in the analysis.
Discussion
This longitudinal observational study of 7410 children pro-
vides the first characterisation of rapid progressors in children
with HLA-conferred disease susceptibility recruited from the
general population. We observed that individuals with aggres-
sive islet autoimmunity and rapid progression to type 1 diabe-
tes can be identified from the general population by demo-
graphic, genetic and immunological characteristics present at
seroconversion. Characterising rapid progression is important
because the incidence of type 1 diabetes has been progressive-
ly increasing in most Western countries over the past few
decades, while age at diagnosis has decreased [21, 22]. This
has raised the question of whether the increasing incidence is a
result of more aggressive and earlier autoimmune responses in
prediabetic individuals [23].
Individuals with rapid disease progressionwere characterised
by a young age, higher prevalence of the high-risk HLA geno-
type, higher autoantibody titres and a higher rate of positivity for
multiple autoantibodies compared with non-progressors. In ad-
dition, a higher proportion of rapid progressors carrying the
high-risk HLA genotype were homozygous for the major G
allele in theFUT2 gene. Compared with individuals with slower
disease progression, rapid progressors had a higher frequency of
multipositivity, higher ICA, IAA and IA-2A titres at serocon-
version, and a higher frequency of homozygosity for the major
G allele in the FUT2 gene in individuals carrying the high-risk
HLA genotype. Sex did not appear to influence the progression
rate. The multivariate analysis identified the high-risk HLA ge-
notype, age at seroconversion, multiple autoantibody, ICA and
IAA positivity, and high ICA titre at seroconversion as predic-
tors of rapid disease progression. Our results are in accordance
with previous reports that multiple autoantibodies at a young
age, appearance of IA-2A as the first biochemical autoantibody
and high IAA titres in the first IAA-positive sample increase the
risk of rapid progression to clinical type 1 diabetes in childhood
[24–26].
Earlier studies into progressive beta cell autoimmunity,
mainly focused on identifying factors predicting overall pro-
gression to clinical diabetes, suggested that high ICA titres
Table 6 AAB positivity and genotype: young vs older rapid
progressors
Characteristic Rapid progressors p value
Younga
(n = 36)
Olderb (n = 6)
Boys 20 (56) 5 (83) 0.20
High-risk HLA genotype 19 (53) 2 (33) 0.38
AAB positivity at seroconversion
ICA 21 (58) 5 (83) 0.24
IAA 32 (89) 2 (33) 0.001
GADA 18 (50) 6 (100) 0.02
IA-2A 9 (25) 2 (33) 0.67
Multipositivity 25 (69) 5 (83) 0.49
FUT2 major allele G homozygosityc 11 (65) 2 (100) 0.31
Data are n (%)
a Early childhood (<5 years old)
b Early puberty (>7 years old)
c In those with the high-risk HLA genotype
AAB, autoantibody
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and an early appearance of IAA are the most sensitive predic-
tors of progressive islet autoimmunity in young children [3, 4,
27–30]. In this study, we used the new approach of investigat-
ing factors associated with an increased progression rate in a
comparative setting. Several factors reported to predict overall
progression to clinical diabetes also, in fact, explain the pro-
gression rate, e.g. development of multipositivity at a young
age, high ICA and IAA titres at seroconversion, and persistent
vs fluctuating IAA [24, 26–29, 31–33].
The comparison of rapid progressors with autoantibody-
positive non-progressors was informative because
autoantibody-positive non-progressors probably have protec-
tive characteristics against the initiated islet autoimmunity.
Studying differences between these two groups might reveal
natural immunomodulators, pathomechanisms of type 1 dia-
betes and potential targets for preventive intervention.
Furthermore, it has been suggested that all children positive
for more than two biochemical autoantibodies will eventually
develop clinical type 1 diabetes [24]. Accordingly, a minor
subgroup of non-progressors who develop multiple autoanti-
bodies but remain unaffected during follow-up might com-
prise individuals with ultraslow disease progression who are
at risk of developing clinical type 1 diabetes later in life [25].
Although this study involves the longest observation period
for prediabetic individuals (from birth to early adulthood),
further studies into their fate later in life are needed.
We observed an interesting tendency for rapid progression
to occur in two age peaks: early childhood and early puberty.
The autoantibody profiles of these two subpopulations are
considerably different at seroconversion: young rapid
progressors have a high prevalence and high titres of IAA at
seroconversion, while those who undergo seroconversion in
early puberty are characterised by GADA positivity and high
GADA titres at seroconversion. Neither HLA predisposition
nor the investigated non-HLA SNPs explain these differences.
In particular, the appearance of IAA as the first autoantibody
is characteristic of seroconversion at a young age, whereas
GADA typically appears later [25]. Owing to the study design
that included monitoring older children with longer blood col-
lection intervals, multipositivity at seroconversion may be
more common in older children, especially when involving
IA-2A positivity because this is usually the last autoantibody
to appear and predicts rapid progression to clinical disease [3].
High ICA titres might reflect GADA and/or IA-2A reactivity.
The double-peak age distribution and differences in the auto-
antibody profiles of rapid progressors of various ages raise the
following questions: (1) is disease process similar in all forms
of aggressive beta cell autoimmunity; (2) are environmental
triggers at sensitive stages of development, such as early
childhood and early puberty, important; and (3) should pre-
ventive interventions be different for different subpopula-
tions? The observation that most of the older rapid progressors
had been autoantibody negative less than a year before
seroconversion supports the hypothesis that heterogenous
events trigger rapid disease progression. In contrast, signs of
beta cell autoimmunity leading to slower progression seem to
appear at a similar frequency for ages 5–13 years. These find-
ings suggest that in the future the analysis of prediabetic au-
toantibodies might be targeted to a few selected age points
during childhood, with the first autoantibody assessment tak-
ing place at age 1 year, and the second closer to puberty, e.g. at
age 6 years. The observed differences should, however, be
interpreted cautiously because the subgroups were small.
Rapid progressors carrying the high-risk HLAgenotype have
an increased prevalence of homozygosity for the major G allele
of a SNP within the FUT2 gene, although not the FUT2 SNP
predisposing to type 1 diabetes, which is intriguing [15, 34]. The
FUT2 gene determines human secretor status by encoding
1,2-α-fucosyltransferase (FUT2), an enzyme responsible for
the synthesis of soluble ABO histo-blood group antigens, which
are present in bodily fluids and on intestinal mucosa [35].
Individuals carrying at least one functional FUT2 allele (major
allele G) express ABO antigens in secretions and on the intesti-
nal mucosa (and are thus called secretors), while individuals
homozygous for the nonfunctional minor allele A (in popula-
tions of European origin) lack the functional enzyme and there-
fore soluble ABO antigens (and are called non-secretors) [36].
Our results showed that individuals homozygous for the
functional FUT2 allele G are predisposed to rapid disease
progression when they carry the high-risk HLA-DQB1*02/
*03:02 genotype. The association of this FUT2 supersecretor
genotype with rapid disease progression suggests that higher
levels of soluble ABO antigens in secretions and on the intes-
tinal mucosa might contribute to triggering aggressive beta
cell autoimmunity and accelerated disease progression.
Gene–gene or gene–environment interactions involving the
high-risk HLA genotype may be different in rapid and slower
progressors. As an example, the FUT2 SNP is associated with
rapid progression only in individuals carrying the high-risk
HLA genotype. Further studies are needed to assess the role
of genetic and gene–environment interactions in the determi-
nation of progression rate.
The strengths of this study are the large, general
population-based study cohort and that participants were in-
vited to regular immunological follow-up on the basis of their
HLA predisposition. Follow-up started from birth, thus facil-
itating close collaboration with the families of study partici-
pants. Despite the initially large study cohort, there was only a
modest number of progressors to overt type 1 diabetes (in
particular, rapid progressors), which limited the power of sta-
tistical analyses. Since the definition of rapid progression is
based on practical considerations and is partly data driven, the
generalisability of the results may be limited. However, the
findings suggest that 1.5 years after seroconversion is a mean-
ingful cut-off point to discriminate between rapid and slower
disease progression.
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To conclude, children with aggressive beta cell autoimmu-
nity and rapid progression to type 1 diabetes may be identified
at seroconversion to autoantibody positivity by their demo-
graphic, genetic and immunological characteristics including
young age, high ICA, IAA, GADA and IA-2A titres, positiv-
ity for multiple autoantibodies, and higher prevalence of a
FUT2 gene SNP. Such children might benefit from early met-
abolic surveillance and early treatment to protect them from
developing diabetic ketoacidosis. They might benefit from
aggressive interventions aimed at delaying and preventing
clinical type 1 diabetes. The double-peak age profile in rapid
progressors documents for the first time that rapid progression
to clinical disease may occur in children at early puberty and
not exclusively in children aged under 5 years.
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